• TRADE NAME: Dupixent (Regeneron)
• INDICATIONS: Moderate-to-severe atopic dermatitis
  
• CLASS: Interleukin-4 receptor alpha antagonist, Monoclonal antibody
• HALF-LIFE: N/A

• FDA APPROVAL DATE: 03/28/2017
• CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
  None known
• PREGNANCY: Insufficient evidence to inform drug-associated risk

• See adverse reactions attributed to class:

  Monoclonal antibody

DRUG REVIEW ARTICLE

Click on the DRUG REVIEW ARTICLE tab (above) to see a review of dupilumab in the Taylor & Francis journal Expert Opinion on Drug Safety.

(Note that non-subscribers to the journal will only be able to see an abstract of the article.)